▶︎ CYTOVALE
San Francisco, US · Founded 2013 · Delaware corporation · 122 employees on LinkedIn · 10 known investors
Find your way into ▶︎ CYTOVALE
593 people in our graph share verified history with the ▶︎ CYTOVALE team — schools, employers, funds. One of them is your warm intro.
Cytovale develops microfluidic deformability cytometry technology for immune response diagnostics, with a focus on early detection and diagnosis in hospital settings. The company serves healthcare systems and clinicians with diagnostic instruments and solutions.
Also known as Cytovale
Founders & leadership
▶︎ CYTOVALE was founded in 2013 by Ajay Shah, Henry Tse, and Dino DiCarlo.
Board
Investors · 10
Reported raises · per SEC filings
Form D private placements$31.1M disclosed across 3 rounds · 2017–2020
▶$16.4MraisedJan 2022 · 23 investors · BiotechnologyRule 506(b)
- Dino DiCarloDirector, Promoter
- William BlackledgeExecutive Officer
- Lindy FishburneDirector
- Jack FuchsDirector, Promoter
- Ajay ShahExecutive Officer, Director, Promoter
- Henry TseExecutive Officer
- Jordanna Polis SchutzDirector
- Offering amount
- $20M
- Amount sold
- $16.4M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.4MraisedOct 2019 · 15 investors · BiotechnologyRule 506(b)
- Lindy FishburneDirector
- Jack FuchsDirector, Promoter
- Dino DiCarloDirector, Promoter
- Ajay ShahExecutive Officer, Director, Promoter
- Jordanna Polis SchutzDirector
- Offering amount
- $8.4M
- Amount sold
- $7.4M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.2MraisedDec 2017 · 7 investors · OtherRule 506(b)
- Lindy FishburneDirector
- Ajay ShahExecutive Officer, Director, Promoter
- Dino DiCarloDirector, Promoter
- Jack FuchsDirector, Promoter
- Offering amount
- $11M
- Amount sold
- $7.2M
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Cytovale is a medical device and diagnostics company whose lead product, IntelliSep, is an FDA-cleared in vitro diagnostic test for adult patients presenting to the emergency department with signs and symptoms of infection. The test runs on the Cytovale medical device and risk-stratifies patients according to their probability of having sepsis with organ dysfunction manifesting within the first three days after testing, returning results in approximately eight minutes so that results can be received alongside other STAT tests.
Rather than detecting a pathogen, IntelliSep measures the host immune response to infection by analyzing the biomechanical properties of white blood cells, which the company presents as a highly sensitive measure of immune activation. Results are intended to be interpreted together with other clinical observations and laboratory results. The company positions the test as addressing the absence of an objective, highly sensitive detection tool for sepsis comparable to those used for other time-sensitive emergencies such as heart attack and stroke.
Traction
The company reports FDA clearance for IntelliSep and cites peer-reviewed and multicenter research, including a study on the test's influence on emergency department physicians' sepsis diagnostic decisions and a multicenter study of clinical and operational outcomes following expansion of the test across a health system. Claimed site-level benefits, described as one site's experience, include reduced use of blood cultures and antibiotics, shorter length of stay, improved ED throughput and fewer overhead sepsis alerts.
Latest developments
In January 2026 IntelliSep was named to Modern Healthcare's Best in Business list for the second consecutive year. In March 2026 the company announced a peer-reviewed study on IntelliSep's influence on emergency department physicians' sepsis diagnostic decisions and a multicenter study reporting reproducible clinical and operational gains after the test was expanded across a health system. In April 2026 Cytovale appointed Eric Khairy as Chief Marketing Officer.
▸Full profile — market position, technology, go-to-market
Market position
Cytovale markets IntelliSep as an objective sepsis detection tool in a setting where, according to the company, a highly sensitive diagnostic test for sepsis had previously been unavailable. IntelliSep was named to Modern Healthcare's Best in Business list for a second consecutive year.
Technology
IntelliSep evaluates the immune response to infection by measuring the biomechanical properties of white blood cells, producing a probability that sepsis with organ dysfunction will manifest within three days of testing. The assay runs on a dedicated Cytovale instrument and delivers results in roughly eight minutes.
Go-to-market
Hospitals and health systems, specifically emergency departments and hospital laboratories. Cytovale addresses physicians, nurses, laboratorians and hospital administrators as distinct audiences for IntelliSep.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
3 people who came through ▶︎ CYTOVALE went on to found or lead other companies.
Competitors · 3
by search overlap
Companies competing with ▶︎ CYTOVALE for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 4
launches, deals, and filingsCytovale announced the appointment of Eric Khairy as Chief Marketing Officer.
A peer-reviewed study reported that IntelliSep influences emergency department physicians' sepsis diagnostic decisions.
A multicenter study reported reproducible clinical and operational gains following expansion of the IntelliSep sepsis test across a health system.
Cytovale's IntelliSep test was named to Modern Healthcare's Best in Business list for the second year in a row.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 1
primary sources listed
- ▶︎ CYTOVALEcytovale.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does ▶︎ CYTOVALE do?
- Cytovale makes IntelliSep, an FDA-cleared emergency department test that assesses sepsis risk in about 8 minutes.
- Who founded ▶︎ CYTOVALE?
- ▶︎ CYTOVALE was founded by Ajay Shah, Henry Tse, Dino DiCarlo in 2013.
- Who are ▶︎ CYTOVALE's investors?
- ▶︎ CYTOVALE's investors include Alumni Ventures, Basecamp Fund, Blackhorn Ventures, Breakout Labs, Breakout Ventures, EMV Capital, IT-Farm Corporation, Norwest Venture Partners and 2 more.
- How much funding has ▶︎ CYTOVALE raised?
- ▶︎ CYTOVALE has disclosed $31.1M raised across 3 rounds.
- Where is ▶︎ CYTOVALE headquartered?
- ▶︎ CYTOVALE is headquartered in San Francisco, US.